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Abstract
CHIR-AB1 is a newly identified avian immunoglobulin receptor that includes both activating and
inhibitory motifs and was therefore classified as a potentially bifunctional receptor. Recently, CHIR-
AB1 was shown to bind the Fc region of chicken IgY and induce calcium mobilization via association
with the common γ-chain, a subunit that transmits signals upon ligation of many different
immunoreceptors. Here we describe the 1.8Å resolution crystal structure of the CHIR-AB1
ectodomain. The receptor ectodomain consists of a single C2-type immunoglobulin (Ig) domain
resembling the Ig-like domains found in mammalian Fc receptors such as FcγRs and FcαRI. Unlike
these receptors and other monomeric IgSF members, CHIR-AB1 crystallized as a two-fold symmetric
homodimer that bears no resemblance to variable or constant region dimers in an antibody. Analytical
ultracentrifugation demonstrated that CHIR-AB1 exists as a mixture of monomers and dimers in
solution, and equilibrium gel filtration revealed a 2:1 receptor-ligand binding stoichiometry.
Measurement of the 1:1 CHIR-AB1/IgY interaction affinity indicates a relatively low affinity
complex, but a 2:1 CHIR-AB1/IgY interaction allows an increase in apparent affinity due to avidity
effects when the receptor is tethered to a surface. Taken together, these results add to the structural
understanding of Fc receptors and their functional mechanisms.
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Introduction
Antibodies are critical components of the adaptive immune system that allow specific
recognition of a remarkable repertoire of pathogens. In addition to direct neutralization of target
antigens, antibodies also participate in the regulation of both adaptive and innate immune
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mechanisms via interactions with Fc receptors (FcRs)1. Association with FcRs induces
inflammatory responses mediated by macrophages, mast cells, neutrophils and natural killer
(NK) cells1. Importantly, FcRs not only trigger the immune response, but also control and limit
its magnitude, thus providing a crucial mechanism to balance between immunological
tolerance and activation2; 3.
In light of the multiples roles of FcRs and their involvement in various pathological disorders,
a detailed understanding of the structure and function of FcRs has become a subject of
increasing interest. In mammals, immunoglobulin superfamily (IgSF) member FcRs have been
identified that are specific for different immunoglobulin classes (including IgG, IgA, IgE and
IgM)1; 4. Current crystallographic data (available for FcγRIIa, FcγRIIb, FcεRI and FcαRI)5;
6; 7; 8; 9; 10; 11; 12 show a similar overall structure composed of two extracellular
immunoglobulin (Ig)-like domains known as D1 and D2 (corresponding to the membrane distal
and membrane proximal domains, respectively). Each of the two domains adopts a typical Ig-
like fold that includes two antiparallel β sheets connected by a conserved intradomain disulfide
bond.
The origin of IgSF FcRs is not clear, but previous observations suggested that these receptors
are evolutionary related to MHC class I-binding proteins13. Indeed, one FcR, FcαRI, is encoded
within the leukocyte receptor cluster (LRC), a conserved genomic region that expresses a large
number of IgSF receptors that are thought to have diverged from a common ancestor. In
humans, these genes include the MHC class I-binding receptors KIRs and LIRs (killer and
leukocyte Ig-like receptors, respectively) and the NK activating receptor NKp4614. A common
feature shared by many LRC-encoded genes is the expression of both inhibitory and activating
counterparts that deliver opposing signals upon binding to the same ligand15. Activating
receptors are characterized by a relatively short cytoplasmic tail and a charged amino acid in
the transmembrane domain that facilitates association with adaptor molecules such as the
common γ-chain, a signaling protein that triggers activation15. The inhibitory receptors express
a relatively longer cytoplasmic tail and carry at least one immunoreceptor tyrosine inhibitory
motif (ITIM), which interacts with cytosolic phosphatases to attenuate activation signals15.
Recently, a new family of chicken Ig receptors (CHIRs) with homology to human LIRs and
KIRs was identified13; 16; 17. The CHIRs are encoded on chicken chromosome 31 in a region
that corresponds to the mammalian LRC17; 18 and includes a large family of highly
polymorphic genes predicted to encode both activating (CHIR-A), inhibitory (CHIR-B), or
bifunctional (CHIR-AB) receptors16; 17. Interestingly, one of these receptors, CHIR-AB1, was
shown to function as a classical FcR expressed on chicken B cells, macrophages, monocytes
and NK cells19. Unlike mammalian FcRs that include two or three extracellular Ig-like domains
and carry either activating or inhibitory motifs1, CHIR-AB1 is composed of a single Ig-like
domain and is classified as a bifunctional receptor due to the expression of both a charged
amino acid in its transmembrane domain and an ITIM motif in its cytoplasmic tail. A specific
interaction between CHIR-AB1 and the Fc portion of IgY, the avian counterpart of mammalian
IgG, was shown to enhance calcium release in a chicken B cell line expressing CHIR-AB1 and
the common γ chain19. Notably, the activation required aggregation of IgY, thus suggesting
that immune complexes are required to trigger an activating response19.
Here we describe the 1.8Å crystal structure of the extracellular domain of CHIR-AB1.
Although the overall structure of CHIR-AB1 closely resembles Ig-like domains found in other
immunoreceptors, CHIR-AB1 differs from mammalian FcRs and LRC members in its ability
to form homodimers. We provide biochemical evidence for the formation of CHIR-AB1 dimers
in solution and characterize the stoichiometry and binding affinity to IgY. Based on these
observations, we suggest a general mechanism by which bifunctional receptors mediate their
dual function.
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Results
Overview of the structure of CHIR-AB1
The extracellular domain of CHIR-AB1 (residues 1–93 of the mature protein) was expressed
as a secreted protein in insect cells. Purified CHIR-AB1 migrated as two peaks on a gel filtration
column suggesting more than one oligomeric state (Figure 1a). Re-injection of the dimer peak
over a gel filtration column resulted in partial dissociation of the dimers and the appearance of
monomers, thus suggesting that dimer formation is concentration dependent. To further
characterize the oligomeric state of CHIR-AB1, we performed sedimentation velocity
analytical ultracentrifugation. The sedimentation profile was analyzed by a continuous c(M)
Lamm equation model resulting in two peaks with calculated average molecular weights
corresponding to 14.3kD and 25.0kD (Figure 1b). As the molecular weight of the monomeric
CHIR-AB1 is 13.4kD (determined by mass spectrometry, data not shown), these results
demonstrated that CHIR-AB1 formed both monomers and dimers in solution. The monomeric
fraction of CHIR-AB1 was isolated by gel filtration chromatography and crystallized in space
group P3121 with one molecule per asymmetric unit. The structure was solved by molecular
replacement using the D1 domain of KIR2DL120 as a search model and refined to 1.8 Å (Table
1).
The CHIR-AB1 ectodomain is a C2-type IgSF domain21 with eight β-strands assembled into
two antiparallel β-sheets. The first β-sheet is formed by strands A, B and E, and the second
sheet is formed by strands C, C’, F, G and G’ (Figure 1c,e). The sheets are connected by a
disulfide bridge involving Cys24 and Cys71 on strands B and F, respectively. The final β-
strand in the structure is divided into two short segments, G and G’, which are separated by
six residues in a left-handed polyproline II helical conformation. The side chains of two serines
in this motive form hydrogen bonds with main chain atoms of strand F (Figure 1d). This type
of interaction was suggested to contribute to the stability of the core Ig fold and is conserved
among many Ig-like domains including the CHIR-related receptors such as KIRs20, LIRs22,
NKp4623 and Fc receptors5; 6; 7; 8; 9; 10; 11; 12. Other features of the CHIR-AB1 structure
include ordered carbohydrate in the CC’ loop attached to Asn38, one of two potential N-linked
glycosylation sites in the CHIR-AB1 ectodomain, and a 310 helix in the EF loop (Leu63-Ala65).
CHIR-AB1 forms homodimers
Although the CHIR-AB1 protein used for crystallization was purified from the monomeric
peak, crystal packing created a symmetric CHIR-AB1 dimer in which residues at the CC’FGG’
face interact across a crystallographic two-fold axis (Figure 2). Most of the dimerization surface
involves the N-terminal tip of the CHIR-AB1 Ig-like domain. At the C-terminal tip of the Ig-
like domain, the subunits of the dimer are separated. The C-termini of the model of each subunit
connect to a linking region in an orientation that would allow anchoring to a common membrane
(Figure 2c), compatible with dimerization in cis at the surface of a cell.
The dimer interface consists of a central hydrophobic patch surrounded by hydrophilic residues
(Figure 2a,b) and includes 16 ordered water molecules involved in hydrogen bonds connecting
the two subunits. To compare the CHIR-AB1 dimer to other protein-protein interactions, we
calculated the shape complementarity index (SC)24, an index that varies from 0 (not
complementary) to 1 (a perfect fit). The CHIR-AB1 dimer has a high SC value of 0.74,
indicating a complementary fit, as compared to 0.64–0.68 for typical antibody/antigen
interfaces24. However, the inclusion of water molecules at the dimer interface and the relatively
small buried surface area (740 Å2 per subunit, as compared with 780 – 850 Å2 per subunit in
typical protein-protein interactions25) is consistent with a monomer-dimer equilibrium, as
observed in solution (Figure 1a,b), rather than obligate dimerization.
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An analysis of electrostatic potentials reveals that the dimer interface includes a positive patch
dominated by Arg72 and a negative patch dominated by Asp44 (Figure 2d). The negative and
positive patches are paired symmetrically in the dimer, allowing complementary interactions
between oppositely-charged counterions on each monomer – thus Arg72 from each subunit
forms a salt bridge with Asp44 from the partner subunit (Table 2 and Figure 2a,b). Below the
dimer interface (as oriented in Figure 2c), a cluster of negatively-charged residues creates
electrostatic repulsion that pushes the subunits apart, and perhaps prevents a close interaction
with negatively-charged lipid head groups at the membrane-proximal portion of the dimer.
Steric restrictions caused by N-linked carbohydrate attached to Asn38 may also prevent a close
approach of CHIR-AB1 to the membrane and facilitate orientation in the “upright” position
depicted in Figure 2c.
Comparison of CHIR-AB1 with related IgSF immunoreceptors
Although CHIR-AB1 binds and responds to the Fc region of chicken IgY, thus establishing its
function as a classical Fc receptor19, it shares only low sequence identity with other known
IgSF FcRs (< 28%)13. Its closest mammalian relative is not a FcR, but rather the MHC class
I-binding receptor KIR2DL1 (33% identity). Superimposition of CHIR-AB1 with the D1
domain of KIR2DL120 results in a root mean square (r.m.s) deviation of 2.5 Å (for 92 carbon-
α atoms) (Figure S1a). While the overall folding topologies are similar, KIR2DL1 is
monomeric20 and differs considerably from CHIR-AB1 in the length and conformations of its
loops. In particularly, significant differences are found in the CC’ and FG loops, which
participate in the CHIR-AB1 dimer interface. KIR2DL1 D1 also lacks counterparts of the
CHIR-AB1 Asp44 and Arg72 residues and the corresponding positive and negative patches
that facilitate CHIR-AB1 dimerization (Figure S1d). Another structural difference between
CHIR-AB1 and KIR2DL1 is that the A strand in CHIR-AB1 does not switch to join the CC’FG
face. Although the CHIR-AB1 structure includes a cis-proline (Pro10) in strand A that is
conserved with KIRs, the break it introduces into strand A is not followed by a switch to the
opposite β-sheet to create an A’ strand, as occurs in KIRs20; 26; 27; 28. The absence of an A’
strand in CHIR-AB1 is notable since this feature is shared by most C2-style Ig-like domains
and is found among many related proteins besides KIRs, including LIRs22; 29 and mammalian
FcRs5; 6; 7; 8; 9; 10; 11; 12.
A search of available structures in the Protein Data Bank30 using the DALI server31 identified
the activating receptor of human NK cells, NKp46, as the closest structural homologue of
CHIR-AB1. The NKp46 ectodomain contains two closely-related Ig-like domains23; 32 that
share a low level of sequence identity with CHIR-AB1 (28.6% and 29.2% for D1 and D2,
respectively). Structural alignments show that CHIR-AB1 most closely resembles NKp46-D1,
resulting in a r.m.s deviation of 1.4 Å (89 carbon-α atoms, Figure S1c). Differences are
observed mostly in the C’E and FG loops and in the absence of the A’ strand in CHIR-AB1.
When compared only to the structures of other IgSF FcRs, the FcR with the highest structural
similarity to CHIR-AB1 is the D1 domain of FcαRI (r.m.s deviation of 2.9 Å for 88 carbon-
α atoms; Supplemental Figure 1b). Given that the Fc binding site on FcαRI differs from the
counterpart region on CHIR-AB1 (Supplemental Figure 1b), it is unlikely that the two proteins
share a common mode of binding to Fc regions.
Stoichiometry of the CHIR-AB1/FcY complex
Classical IgSF FcRs have previously been shown to interact with their Fc ligands with a
stoichiometry of either 1:1 (FcγRs and FcεRI) or 2:1 (FcαRI)4. To determine the stoichiometry
of the CHIR-AB1/FcY interaction, we used equilibrium gel filtration chromatography. In this
form of chromatography, gel filtration is conducted under equilibrium conditions by including
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one of the binding partners in the running buffer33, thereby preventing dissociation of weak
complexes that could result in an altered stoichiometry.
In our experiments, a gel filtration column was equilibrated with and run in a buffer containing
a fixed concentration of purified monomeric CHIR-AB1. Samples containing different ratios
of CHIR-AB1 to FcY were injected onto the column in the equilibration buffer. Figure 3a
shows the elution pattern of CHIR-AB1/FcY complexes obtained at the indicated injected
ratios over a column equilibrated with 2.5µM CHIR-AB1. A trough corresponding to the
position where CHIR-AB1 migrates was observed when sample contained CHIR-AB1 mixed
with FcY at 1:1 molar ratio, indicating a depletion of the receptor in the running buffer. The
depth of the trough was reduced at a 2:1 ratio of CHIR-AB1 to FcY, and was replaced by a
positive peak at CHIR-AB1:FcY ratios of 3:1 and 4:1 (Figure 3a). Similar sets of injections
were performed with 1.5µM, 5µM and 10µM CHIR-AB1 in the equilibration buffer (data not
shown). By determining the ratio of injected proteins at which no peak or trough appears at a
series of concentrations of CHIR-AB1 in the equilibration buffer, the data could be converted
into a Scatchard plot, allowing determination of both the stoichiometry and solution phase
affinity34 (Figure 3b). The Scatchard plot shows an x-intercept of 1.8, which is most consistent
with a 2:1 CHIR-AB1:FcY stoichiometry, such that two CHIR-AB1 molecules bind per
homodimeric FcY. The derived solution phase affinity corresponds to an equilibrium
dissociation constant (KD) of ~840nM.
A solution phase affinity does not take into account potential avidity effects that can occur in
a 2:1 receptor:ligand interaction. An increased apparent affinity due to avidity can result when
a ligand cross-links receptors attached to a membrane or other surface. Indeed, when we used
a 1:1 binding model to analyze binding data for IgY injected over CHIR-AB1 immobilized on
a biosensor surface, we derived a macroscopic, or apparent, KD of 17 ± 9 nM (Figure 4a). This
value is similar to a recently-reported KD derived from a SPR analysis of IgY binding to
immobilized CHIR-AB1, which also assumed 1:1 binding19. We also analyzed the binding
data in Figure 4a using a stepwise, or sequential, binding model (bivalent analyte binding
model), which yielded microscopic KD values of 403 ± 30 nM and 3.9 ± 1.5 µM for the binding
of the first and second CHIR-AB1 molecules to IgY. These values are consistent with KD
values derived under conditions in which cross-linking could not increase the apparent affinity
through avidity effects: ~840nM calculated from the equilibrium gel filtration experiments in
solution (Figure 3b) and ~800nM derived from SPR experiments in which CHIR-AB1 was
injected over immobilized IgY (Figure 4b).
Localization of the FcY-binding site on CHIR-AB1
CHIR-AB1 belongs to a large family of highly polymorphic genes that show a high degree of
sequence similarity17. Surprisingly, CHIR-AB1 is the only CHIR family member found to
interact with IgY; other CHIR receptors, including CHIR-A2, CHIR-B2, CHIR-B3 and CHIR-
AB3, exhibited no binding to IgY19. To gain insight into which residues confer the ability to
bind IgY onto a CHIR protein, we mapped the amino acids differences between CHIR-AB1
and CHIR-AB2, which are related by 87% amino acid identity (Figure 5a), onto the CHIR-
AB1 structure. To evaluate the potential significance of amino acid differences between CHIR-
AB1 and CHIR-AB2, we compared these sequences to sequences of other non-IgY-binding
CHIRs (CHIR-A2-D1, CHIR-B2-D1, and CHIR-B3-D1).
Comparison of the differences between CHIR-AB1 and -AB2 shows a cluster of unconserved
amino acids located at the membrane distal portion of the receptor (Figure 5b), suggesting that
the FcY binding site involves this surface. Interestingly, some of the non-conserved amino
acids overlap with residues at the dimerization interface (highlighted in red in Figure 5a,b).
For example, Asp44, which is critical for dimerization of CHIR-AB1, is not conserved in any
of the non-IgY binding CHIR members. Substitution of Asp44 for an uncharged residue is
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unlikely to allow dimerization in the other CHIRs, since residue 44 pairs with a positively-
charged residue, Arg72, in the CHIR-AB1 dimer. Notably, in the case of CHIR-AB2, residue
44 is a lysine, whose positive charge is likely to hinder dimerization due to electrostatic
repulsion with Arg72. Whether dimerization is required for FcY binding remains to be
demonstrated, but these results suggest that, in addition to being unable to bind FcY or IgY,
CHIR-AB2 does not dimerize.
Discussion
Here we report the biochemical and structural characterization of CHIR-AB1, a non-
mammalian classical FcR identified in the chicken genome. Based on chromosomal
localization and sequence similarities, CHIR-AB1 was recognized as a member of the chicken
LRC family17, suggesting a close evolutionary relationship with mammalian LRC members.
In agreement, the crystal structure of CHIR-AB1 reveals structural similarity to the canonical
Ig-like domains found in the membrane-distal D1 domains of mammalian LRC genes, and
shows closer similarity to FcαRI, an LRC member, than to other FcRs. The relation between
CHIR-AB1 and FcαRI is also highlighted by the 2:1 binding stoichiometry of both receptor:Fc
interactions as compared with the 1:1 stoichiometry for the interactions of other IgSF FcRs
with Fcs4.
Interestingly, despite low sequence identity (less than 29%), the closest structural homologue
of CHIR-AB1 is the D1 domain of NKp46, an LRC member that is exclusively expressed on
NK cells and plays a critical role in the recognition and killing of NK targets including tumors
and virally infected cells35. Although NKp46 can bind to a variety of target cells, the nature
and identity of its specific ligands is largely unknown – the only identified NKp46 ligand is
influenza virus hemagglutinin, which binds and activates NKp46 in a sialic acid-dependent
manner36; 37. The binding of NKp46 to hemagglutinin and putative tumor ligands depends
entirely on the D2 domain of the receptor, thus the function of the NKp46 D1 domain is not
clear38. In light of its striking similarity to CHIR-AB1, knowledge of the mode by which CHIR-
AB1 binds its FcY ligand may shed light on the unknown function and binding properties of
NKp46-D1.
Our findings reveal that CHIR-AB1 is unique among classical FcRs not only in its single Ig-
like domain, but also in its ability to form symmetric homodimers. The dimerization of CHIR-
AB1 was independent of FcY and was observed in crystals and in solution, as confirmed by
size exclusion chromatography and analytical ultracentrifugation assays. Importantly, CHIR-
AB1 is not an obligate homodimer; rather it exists in solution as a mixture of monomers and
dimers. Such dimers may also occur at the surface of the cell where clustering could facilitate
dimerization. Indeed, the presence of water molecules at the dimer interface is consistent with
dimerization being a dynamic reversible process, which is also suggested by the observation
that purified monomeric CHIR-AB1 crystallized as a dimer and purified dimers dissociated
into monomers upon storage and/or dilution (data not shown).
The location of the CHIR-AB1 binding site on IgY is currently unknown. The Fc region of
IgY, in common with Fc regions of mammalian IgM and IgE, contains three constant regions:
CH2, CH3, and CH4, where the CH3 and CH4 domains are the counterparts of the CH2 and
CH3 domains in an IgG Fc. In both this and a previous study19, the FcY fragment used for
binding studies contained only the CH3 and CH4 domains, thus we know that the CH2 domains
of FcY are not critical for binding to CHIR-AB1. Based on the 2:1 CHIR-AB1:FcY binding
stoichiometry and the observation of CHIR-AB1 dimers, we can consider several options for
the binding site within the CH3-CH4 domains of FcY (Figure 5c). One possibility is that CHIR-
AB1 interacts with the N-terminal region of two FcY CH3 domains in an asymmetrical manner,
analogous to the FcεRI-IgE and FcγR-IgG interactions4. In these examples, binding of the
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monomeric FcR to the lower hinge region and the CH2 domain of the IgG Fc or the CH3 domain
of the IgE Fc induces structural asymmetry and steric interference that prevents binding of a
second receptor to the symmetry-related location on the dimeric Fc, resulting in a 1:1 complex.
Since CHIR-AB1:FcY forms a 2:1 complex, this mode of interaction can only be envisioned
if FcY binds dimeric CHIR-AB1, thus implying that receptor dimerization is required for FcY
binding. A second possibility, analogous to the interaction between FcαRI and IgA39, is that
CHIR-AB1 binds to the interface between the FcY CH3 and CH4 domains, a region analogous
to the “hotspot” for receptor binding to IgG Fc40. In this case, a 2:1 CHIR-AB1/FcY
stoichiometry could only be achieved if monomers of CHIR-AB1 bind to each chain of the
FcY homodimer. A third possibility, as yet unprecedented among FcRs, is that the two-fold
symmetry axes of the CHIR-AB1 dimer and FcY align, such that each subunit of a CHIR-AB1
dimer binds an equivalent site on a symmetrical FcY dimer. This mode of binding would
probably only be possible at the base of the FcY CH4 domains, as the analogous symmetric
site on the CH3 domains would likely be blocked by the CH2 domains. Although this mode of
interaction has not been seen in other FcR/Ig interactions, CHIR-AB1 is the only classical FcR
that forms symmetrical dimers, thus it may have different binding properties than other known
FcRs.
Cross-linking of surface receptors is recognized as a general mechanism by which ligand
binding induces signal transduction and receptor activation. Since immune complexes of IgY
are required for activation of cell surface CHIR-AB119, spontaneous dimerization of CHIR-
AB1 is not likely to deliver activation signals. This assumption is supported by the structure
of a CHIR-AB1 dimer, in which the C-termini of the two subunits are separated by ~45Å,
suggesting that the connecting transmembrane domains of two interacting monomers would
be too far apart to trigger a response. Binding of IgY-immune complexes may therefore be
required to initiate clustering that would bring several receptors into proximity to trigger a
signaling event.
Alternatively, it is possible that constitutive activation is inhibited by the presence of the ITIM
motif in the CHIR-AB1 cytoplasmic tail. Although an inhibitory function for CHIR-AB1 has
not been observed, the presence of an ITIM motif in its cytoplasmic tail is consistent with an
inhibitory function that may be relevant under specific conditions or in particular cell types.
The concept of activating receptors counterbalanced by inhibitory partners that interact with
the same ligands is a repeating theme in the vertebrate immune system and is common among
LRC members. In addition, bifunctional receptors have been identified in primates, including
KIR2DL4 and NKp4441. Although both receptors were originally identified based on their
ability to enhance NK-mediated cytotoxicity in activated NK cells42; 43; 44; 45 further studies
demonstrated that KIR2DL426 and NKp4446 can also function as inhibitory receptors.
Interestingly, the possibility that NKp44 can dimerize was recently suggested based on the
observation of NKp44 dimers in the crystal lattice47. Further studies are required to evaluate
the functional relevance of the ITIM motif in the cytoplasmic tail of CHIR-AB1 and the
physiological significance of CHIR-AB1 dimerization.
Material and methods
Protein Expression and Purification
The cDNA encoding the extracellular domain of CHIR-AB1 (residues Gln1-Thr 95 of the
mature protein) (GenBank accession no. AJ745094) was subcloned into the pAcGP67A
baculovirus transfer vector (BD Biosynthesis), which includes a gp67 secretion signal, in frame
with a C-terminal 6xHis tag sequence. Recombinant baculoviruses were generated by
cotransfection of the transfer vector with linear DNA (Baculogold, BD Biosynthesis).
Supernatants were harvested from Hi5 insect cells, and then concentrated and buffer exchanged
against 40mM Tris, 300mM NaCl, pH 8. The expressed protein was purified using Ni-NTA
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affinity chromatography (Ni-NTA Superflow, Qiagen) followed by size exclusion column
chromatography on a Superdex 75 16/60 column (Amersham Biosciences).
The cDNA encoding the CH3-CH4 domains of chicken IgY (residues 279–504 of the mature
protein, referred to as ‘FcY’) was subcloned into the pAcGP67A baculovirus vector (BD
Biosynthesis) in frame with an N-terminal 6xHis tag. FcY was expressed and purified as
described for CHIR-AB1, except that the final purification step was done using a Superdex
200 16/60 column (Amersham Biosciences).
IgY was purchased from Jackson ImmunoResearch Laboratories and purified by gel filtration
chromatography using a Superdex 200 16/60 column (Amersham Biosciences).
Protein concentrations were determined spectrophotometrically by measuring absorption at
280nm using extinction coefficients of 19,480 M−1cm−1 for CHIR-AB1, 11,200 M−1cm−1 for
FcY, and 10,860 M−1cm−1 for IgY (calculated using the ProtParam tool on the ExPasy
proteomic server).
Crystallization, Data Collection and Processing
Crystals of CHIR-AB1 were grown at 22°C in 1:1 hanging drops containing CHIR-AB1 (10–
24mg/ml) and 2M ammonium sulfate. Single crystals were transferred to a cryoprotectant
containing 2.2M ammonium sulfate and 25% glycerol prior to data collection. The crystals
belong to space group P3121 (a = 63.69Å, b = 63.69Å, c = 55.45Å; one molecule per
asymmetric unit). Data were collected to 1.8Å resolution at −170°C from a single crystal using
an R-AXIS VII mounted on a Rigaku RU-200 rotating anode generator. Data were processed
and scaled using HKL 2000.
Structure solution, Refinement and Analysis
To generate suitable protein models for molecular replacement calculations, a FFAS03 search
against sequences with known structures was preformed48. For the ten highest scoring
templates, an all-atom homology model and a 'mixed' model (non-identical sidechains replaced
by serine) were built by the SCWRL server49. These models were input in various combinations
into the programs PHASER50, MOLREP, and AMORE in space groups P321, P3121 and
P3221. As crystallographic R-factors for most solutions were between 50% and 60%, a clear
identification of a solution by data statistics alone was not possible, but visual inspection of
the resulting electron density maps showed features not present in the original search model
in a solution obtained by PHASER using a mixed model of PDB entry 1VDG in space group
P3121. This potential solution (Z-score 7.1, LLG 67, initial Rcryst/Rfree 56%) was subjected to
initial refinement using REFMAC51, which reduced the R values to 45% (Rcryst) and 53%
(Rfree). The model was subsequently rebuilt using ARP/Warp52 and manual corrections. The
complete model was refined at 1.8Å to a final Rcryst/Rfree of 22.1% and 24.6% with good
geometry (Table 1). The final model consists of residues 1–93 of the mature CHIR-AB1
ectodomain, 116 water molecules and 38 atoms of carbohydrate [ordered carbohydrate was
observed attached to the asparagine of one of the potential N-linked glycosylation sites
(Asn38), but not to the other (Asn83)]. The sidechain of residue Glu63 was disordered and
modeled as alanine. A disulphide bonds was observed between CHIR-AB1 residues Cys24
and Cys71.
Shape complementarity indices (SC) were calculated as described24 using the Sc program in
the CCP4 suite53. Superimpositions were preformed using PyMol and the Combinatorial
Extension (CE) Method58. Buried surface areas were calculated using the Protein interfaces,
surfaces and assemblies service (PISA) at the European Bioinformatics Institute
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(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html)57. Figures were generated using
PyMOL40 (The PyMOL Molecular Graphics System, http://www.pymol.org).
Analytical Ultracentrifugation
Sedimentation velocity analytical ultracentrifugation experiments were performed at 20°C in
a Beckman XL-I Ultima analytical ultracentrifuge using absorbance optics. CHIR-AB1 was
freshly purified on a Superdex 75 16/60 column and loaded (420 µl, 9.4µM) into two-channel
velocity cells with sapphire windows. Samples were spun at 55,000 rpm and 20°C, and
absorbance scans were taken using the continuous scan mode as one replica with a point spacing
of 0.003 mm. Data were analyzed using a continuous c(M) distribution model (direct fitting
of the Lamm equation) with the program SedFit (www.analyticalultracentrifugation.com).
Partial specific volume, buffer density, and viscosity values were calculated to be 0.712 ml/g,
1.00535 g/ml and 0.001002 poise, respectively, using the program Sednterp version 1.08.61.
The partial specific volume of CHIR-AB1 was adjusted to reflect two N-linked glycosylation
sites, predicted from the amino acid sequence and confirmed by mass spectrometry (data not
shown).
Equilibrium Gel Filtration
The equilibrium gel filtration method33 including Scatchard analysis34 was used to analyze the
association of CHIR-AB1 with FcY, as described previously54; 55. Chromatography was
performed at a flow rate of 0.1 mL/min using a SMART micropurification system (Pharmacia).
A Superdex 200 PC 3.2/30 gel filtration column was equilibrated with and run in 20 mM Tris
pH 8.0, 150 mM NaCl containing 1.5µM, 2.5 µM, 5 µM or 10 µM monomeric CHIR-AB1
(equilibration buffer). For each concentration of CHIR-AB1 in the equilibration buffer, a series
of injections were performed in which a fixed concentration of FcY (equal to the concentration
of CHIR-AB1 in the equilibration buffer) was mixed with different concentrations of CHIR-
AB1. Relative trough and peak areas were determined by integrating the CHIR-AB1 elution
region using Excel. In each set of injections, the amount of bound CHIR-AB1 was calculated
as previously described54; 55 and used for Scatchard analysis to determine the stoichiometry
of CHIR-AB1:FcY binding and the solution KD.
Biosensor-based affinity measurements
The interaction between CHIR-AB1 and IgY was evaluated using a Biacore 2000 instrument
(Pharmacia Biosensor, Uppsala, Sweden). To minimize signals resulting from aggregated
proteins, samples were purified by gel filtration chromatography immediately prior to analysis.
Purified CHIR-AB1 or IgY were covalently coupled to a CM5 sensor chip (Biacore) using the
standard primary amine chemistry, as described in the Biacore manual. Proteins were coupled
to a total of 58 resonance units (RUs) for CHIR-AB1 and 2000 RUs for IgY. One flow cell out
of four on the biosensor chip was mock coupled with buffer only for background subtraction.
Measurements were performed at 20°C in 20 mM Hepes pH 7, 150 mM NaCl, and 0.005%
surfactant P20. Increasing concentrations of analyte (injected protein) were injected at a flow
rate of 50 µl/min, and association and dissociation phases were monitored for 7 min. Sensor
signals returned to baseline after each injection without regeneration. After subtracting
reference cell signals, the resulting binding data were globally fit to either a bivalent analyte
or a 1:1 binding model (Biaevaluation software, Biacore). KD values were obtained by
simultaneous fitting of the association and dissociation phases of all curves in the working set.
The bivalent analyte model fits binding data to sequential reactions, deriving microscopic
KD values for the binding reactions that produce singly- and doubly-liganded IgY proteins.
The equilibrium binding constant KD2 was converted from RU units to molar units using the
conversion factor M=RU/(100×molecular mass), based on the molar response in RUs and the
volume of the flow-cell (Biacore AB). Corrections for statistical factors to KD1 and KD2 values
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derived from bivalent ligand models were applied as described54. A 1:1 binding model
produces a macroscopic, or apparent, KD that does not take the avidity effects of a bivalent
analyte (in this case, IgY) into account, thus it results in a higher apparent affinity for the
binding of IgY to immobilized CHIR-AB1 than derived using a sequential binding model.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Structure of CHIR-AB1
(a). Elution profile of purified CHIR-AB1 on a S200 Superdex gel filtration column. The
elution volumes of molecular weight standards are indicated by arrows. (b) Velocity
sedimentation analytical ultracentrifugation analysis of purified CHIR-AB1 showing the
existence of monomeric (14.3kD) and dimeric (25.0kD) forms. Data are displayed at the 95%
confidence level. (c) Ribbon diagram of the CHIR-AB1 structure. β-strands A, B, and E are
shown in blue, strands CC’FGG’ in red, a 310 helix in purple and a polyproline II helix in
green. The disulfide bond is yellow and carbohydrate residues are shown in stick representation.
(d) Close-up view of the region of the polyproline II helix showing hydrogen bonds between
the side chains of Ser 82 and Ser 85 and main chain atoms of residues Arg72 and Cys71. Side
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chains are shown as sticks using atom-based color code (oxygen, red; nitrogen, blue). (e)
Topology diagram of CHIR-AB1. β-strands, 310 helix and the polyproline II helix (P-P) are
colored as above. Contact resides involved in dimerization (Figure 2 and Table 2) are
represented by yellow dots.
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Figure 2. The dimer interface
(a) Dimerization interface region with one subunit as a surface representation (hydrophilic
contact residues in light blue and hydrophobic contact residues in green) and the other subunit
as transparent ribbons diagram colored as in Figure 1b (β-strands A, B, and E are shown in
blue, strands CC’FGG’ in red, a 310 helix in purple and loops are colored grey). Strands are
labeled in white and contact residues are shown as sticks. (b) Cross section of the dimer interface
illustrating the two symmetrical inter-subunit salt bridges (green lines) between Asp44 and
Arg72. Water molecules (yellow spheres) that mediate a hydrogen bond network (yellow dotted
line) between the Gln34 residues of each subunit are also shown. Strands are labeled in
white and colored as above (c) Proposed orientation of a CHIR-AB1 dimer on a membrane
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(grey line). Monomers are colored as in Figure 1b. The two-fold symmetry axis relating the
monomers is indicated by a vertical green dotted arrow in the plane of the page. The distance
between the C-terminus of each ectodomain (45Å) and the approximate length of the
ectodomain (~35Å) are indicated (black dashed lines). The 8-residue stem region connecting
each ectodomain subunit to the transmembrane region is shown as a broken black bar with a
maximum theoretical length of ~30Å (calculated assuming 3.8Å per residue). (d) Molecular
surfaces of the two subunits in a CHIR-AB1 dimer with colors highlighting the electrostatic
potential calculated with APBS tools 56. Electrostatic potential is plotted from −11.2 kT/e
(electronegative; red) to +11.2 kT/e (electropositive; blue) with white indicating
electroneutrality. The right monomer is related to the left monomer by a rotation about the
indicated axis of ~170°. Black arrows point toward contact partner residues.
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Figure 3. CHIR-AB1-FcY binding stoichiometry
(a) Equilibrium gel filtration analysis of the CHIR-AB1-FcY complex. The column was
equilibrated with and run in a buffer containing 2.5 µM CHIR-AB1. Complexes were prepared
by incubating 2.5 µM FcY with varying amounts of CHIR-AB1 at receptor:FcY molar ratios
of 1:1, 2:1, 3:1 and 4:1. Similar experiments were conducted using columns equilibrated with
1.5µM, 5µM and 10 µM of CHIR-AB1 (data not shown). (b) Scatchard plot including data
from equilibration buffers containing 1.5µM, 2.5µM, 5µM and 10µM CHIR-AB1. The best
fit line to the data yields a KD of 840 nM and an x-intercept of 1.83.
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Figure 4. Biosensor analyses of CHIR-AB1/IgY interactions
Representative sensorgrams describing the binding response of increasing concentrations of
IgY injected over immobilized CHIR-AB1 (58RUs) (a) or CHIR-AB1 injected over
immobilized IgY (2000RUs) (b). Colored lines show the observed response overlaid with the
calculated response (black line) based on a 2:1 binding model. Fitting of the same data with a
1:1 binding model resulted with KD values of 17 ± 9nM (a) and 800nM (b). Similar results
were obtained when CHIR-AB1 was coupled to the chip at different densities (140RU, 320RU
and 560RU; data not shown).
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Figure 5. Models for the CHIR-AB1/FcY interaction
(a) Sequence alignment of the extracellular domains of CHIR-AB1 and CHIR AB2 with the
D1 domains of CHIR-A2, CHIR-B2, and CHIR-AB3 (GenBank accession numbers
AJ745094, AJ745095, AJ745093, AJ639837 and AJ879909, respectively). Residues at the
dimer interface of CHIR-AB1 are indicated by asterisks above the sequence. (b) Ribbon
diagram of a CHIR-AB1 dimer with residues that differ from CHIR-AB2 highlighted as red
(dimer interface residues) or blue (all others) sticks. The highlighted amino acids are labeled
(c) Potential models for binding between CHIR-AB1 and IgY. The CHIR-AB1 ectodomain is
blue, the ITIM motif in the cytoplasmic tail is represented by a rectangle, and the cell membrane
is shown as a dotted black line. IgY is shown with a yellow and orange Fc region and grey
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Fabs. (Left) A dimer of CHIR-AB1 is bound asymmetrically to the lower hinge region between
the CH2 and CH3 domains of FcY, analogous to the binding of FcγRs and FcεRI to Fcs. (Middle)
CHIR-AB1 monomers bind to the CH3-CH4 interdomain interface to create a symmetrical 2:1
complex, analogous to the binding of FcαRI to Fc. (Right) The two-fold symmetry axis of a
CHIR-AB1 dimer aligns with the two-fold symmetry axis of FcY to form a symmetric 2:1
complex in which each CHIR-AB1 monomer binds to the bottom of a FcY CH4 domain.
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Table 1
Crystallographic Data and Refinement Statistics
Unit cell Space group P3121
Cell dimensions: a, b, c (Å) 63.9, 63.9, 55.4
Data collection
Resolution (Å) 1.8
aRmerge(%) 4.4 (42.6)
I / σI 41.9 (4.3)
Completeness (%) 95.9 (93.9)
Redundancy 3.8 (3.8)
Refinement statistics
Resolution (Å) 27.7-1.8
No. of unique reflections 12020
No. of reflections used 10932
cRcryst
 / dRfree 0.20/0.24
# atoms (B factor) Protein 737 (28.1 Å2)
Carbohydrate 38 (43.4 Å2)
Water 116 (41.4 Å2)
Model geometry
R.m.s. deviation from ideality:
Bond length (Å) 0.014
Angles (°) 1.667
Ramachandran plot
Most favored (%) 91.4
Additionally allowed (%) 8.6
Generously allowed (%) 0.0
Disallowed (%) 0.0
a
Rmerge = 100 × Σ|I − 〈I〉| /ΣI, where I is the integrated intensity of a given reflection. Values in parentheses are for the highest resolution shell (1.89-1.82
Å).
b
Rcryst = 100 × Σ Fobs − Fcalc ′ /Σ Fobs, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively, for reflections
in the working set.
d
Rfree was calculated for the test set containing randomly chosen reflections (5% of the data) that were not included in the refinement.
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Table 2
Amino acid contacts at the dimer interface
Distance and geometry criteria for assigning hydrogen bonds (HB): a distance of <3.5Å and a hydrogen bond angle
>90°. The maximum allowed distance for a van der Waals (VDW) interaction was 4Å and the salt bridge distance
cutoff was ≤ 3.5Å.
Monomer A residue Partner residue
on monomer B
Distance (Å) Type of interaction Buried surface
area (Å2 per
monomer)
Ala30 Leu79 3.5 VDW 47.1
Ala31 Glu77 4 VDW 10.1
Trp32 Val75 3.1 HB 116.6
Trp80 3.3 HB
Gln34 Gln34 3.6 VDW 20.9
Trp36 Leu41 3.8 VDW 14.4
Thr40 Thr40 3.6 VDW 33.0
Leu41 Trp36 3.8 VDW 62.8
Asp44 Gln34 3.2 HB 39.0
Arg72 2.9 Salt bridge
Glu46 Leu79 3.8 VDW 24.8
Lys47 Leu79 3.7 VDW 2.8
Asp48 Leu79 3.8 VDW 10.8
Arg72 Asp44 2.9 Salt bridge 24.1
Gln74 Asp44 3.2 HB 55.6
Val75 Trp32 3.1 HB 15.7
Ser76 Ser76 3.3 H-bond 72.8
Glu77 Ala31 4 VDW 52.0
Leu79 Ala30 3.5 VDW 120.9
Glu46 3.8
Lys47 3.7
Asp48 3.8
Trp80 Trp32 3.3 HB 4.9
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